Diphacinone and coumatetralyl persistence in deer and implications for wildlife management by Eason, C. T. et al.
 8th European Vertebrate Pest Management Conference 
146 Julius-Kühn-Archiv, 432, 2011 
Diphacinone and coumatetralyl persistence in deer and implications for wildlife 
management 
Eason, C.T.1,2, Murphy, E.3, Ross, J.G.1, Hix, S.2, Arthur, D.4, MacMorran, D.2, Broome, K.3, Fairweather, A.3 
1Centre for Wildlife Management and Conservation, Lincoln University, Lincoln, New Zealand, 
charles.eason@lincoln.ac.nz 
2Connovation Research Ltd, Auckland, New Zealand  
3Department of Conservation, Christchurch and Hamilton, New Zealand 
4Selwyn Rakaia Vet Services Ltd, Dunsandel, New Zealand 
DOI: 10.5073/jka.2011.432.080 
Abstract 
Because of the concerns regarding wildlife contamination following the field use of anticoagulants the 
hepatic persistence of diphacinone and coumatetralyl has been compared in deer. Initial coumatetralyl 
concentrations in liver following oral dosing with 8.25 mg/kg coumatetralyl were similar on day 1 to 
those achieved by administration of diphacinone at 1.5 mg/kg. Coumatetralyl was more slowly 
eliminated (t½ 14 days) than diphacinone (t½ 6 days) and residues were still present in liver tissue after 
50 days versus 12 days for diphacinone. Bioaccumulation on repeated field use is unlikely.  
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Introduction 
The pharmacokinetics of rodenticides determines their tendency to bioaccummulate on repeated 
exposure. Pharmacokinetic research involves dosing animals and taking blood or tissue samples for 
analysis. In this study liver samples were taken for analysis of diphacinone or coumatetralyl since it is 
well known that the highest concentration of these compounds occurs in the liver. Diphacinone is 
reported to have a short hepatic half-life of 3 days in rats (Fisher et al., 2003), and shorter than the 55 
days reported for coumatetralyl in rats (Fisher et al., 2003). The aims of this study were to investigate the 
comparative persistence of diphacinone versus coumatetralyl in deer. The persistence of anticoagulants 
has not previously been reported in deer which could come into contact with rodenticide baits if they are 
used on or near deer farms or in conservation settings to kill predators of ground dwelling birds. 
Methods 
Six young male red deer weighing from 77 to 89 kg were split into two groups of three. Deer were fed 
palatable feed containing 8.25 mg/kg coumatetralyl or 1.5 mg/kg diphacinone. The doses of 8.25 mg/kg 
coumatetralyl and 1.5 mg/kg diphacinone represented ½ the published single dose LD50 in rats for 
coumatetralyl, namely 16.5 mg/kg and for diphacinone, 3.0 mg/kg (Buckle and Smith, 1994). No acute 
toxicity data exists for either of these compounds in deer. Liver biopsies were undertaken with the same 
lobe of the liver sampled on each occasion with repeat samples taken in very close proximity to each 
other. The incision site was located through the 11th intercostal space on the right hand side of each deer. 
A 1-2 g liver biopsy was taken. To minimise trauma a sedative and local anaesthetic was administered as 
outlined in West and Vermut (1995). Analyses of residue concentrations were undertaken on liver 
samples by an established hplc technique. Animal Ethic Approvals were obtained. The half-lives (t½ 
days) for diphacinone and coumatetralyl were determined from the regression as (loge(2)/b), where b is 
the slope of the regression of loge(concentration) against time.   
Results 
Diphacinone concentrations deer liver decreased to below or at the level of detection of 0.05µg/g within 
29 days (see Table 1). The depletion half-life for diphacinone in liver tissue in deer was 6.3 days (+0.8 
SEM). Initial coumatetralyl concentrations in deer liver following dosing with 8.25 mg/kg coumatetralyl 
were similar on day 1 to those achieved by administration of diphacinone at 1.5 mg/kg. However 
residues of coumatetralyl were still present after 50 days in one animal (see Table 2). The depletion half-
life for coumatetralyl in deer was 14.4 days (+3.6 SEM). MDL=0.02 µg/g. 
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Tab. 1 Liver concentrations following oral administration of diphacinone (1.5 mg/kg). 
Day after dosing Individual conc. in µg/g Average concentration µg/g 
  1 0.48, 1.26, 0.22 0.69 
  5 0.24, 0.40, 0.29 0.31 
12 0.41, 0.00, 0.00 0.14 
29 0.00, 0.00, 0.00 0.00 
 
Tab. 2 Liver concentrations following oral administration of coumatetralyl (8.25 mg/kg). 
Day after dosing Concentration in µg/g Average con-centration µg/g 
  1 0.39, 0.66, 0.37 0.47 
  8 0.49, 0.49, 0.41 0.46 
15 0.47, 0.09, 0.09 0.22 
29 0.50, 0.09, 0.00 0.20 
50 0.08, 0.00, 0.00 0.03 
85 0.00, 0.00, 0.00 0.00 
 
Discussion 
Assessments of the persistence of diphacinone and coumatetralyl have been completed in deer and the 
depletion half-life calculated in liver tissue. Coumatetralyl was more slowly eliminated in deer (t½ 14 
days) than diphacinone (t½ 6 days) and residues were still present in liver tissue after 50 days versus 12 
days for diphacinone. Both compounds appear to be more suited for repeated field use versus the more 
persistent second generation anticoagulants with diphacinone being less likely to bioaccummulate than 
coumatetralyl. In contrast with the results obtained with these compounds in deer brodifacoum and all 
other second-generation anticoagulants have unusually long hepatic half-lives in liver in all species tested  
(Laas et al., 1985; Parmar et al., 1987; Huckle et al., 1989a and b). Not surprisingly, given the unusual 
persistence of brodifacoum, residues have been found in game animals such as pigs and deer and a range 
of avian species (Eason et al., 2001). This paper confirms that coumatetralyl and diphacinone are quickly 
eliminated from mammals including deer, which is important in areas where deer may be game for 
hunters. An understanding of the persistence of rodenticides is important when considering rodenticides 
for field use for conservation and in an agricultural setting. Furthermore we believe that the idea of 
revisiting synergists such as low dose cholecalciferol with diphacinone and coumatetralyl, whilst 
presenting registration challenges, has scientific merit in terms of producing rodenticides as potent as 
brodifacoum with reduced hazards to non-target wildlife resulting from bioaccumulation.  
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